本帖最后由 老马 于 2012-1-13 21:20 编辑
/ m+ A1 D! B! q: q, P- y- q1 \- B' z$ s' w& F x& \. A, h0 {
爱必妥和阿瓦斯丁的比较
2 s& n' N" e, E" V" R n* \1 h1 z
% }+ {! n0 t+ x/ e4 V8 i8 chttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/2 r. J2 K5 N4 Q _
1 t4 `7 Q1 `! a/ t6 C
+ z2 u0 h% D4 m! ?+ I$ b
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
0 g$ i1 F' W: P! |: n! r! o4 e==================================================
& t. V1 Y3 x" [! cOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)0 h- ^% V: F8 G# ?
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point., F! | o G: p6 @
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.+ c: c8 M( v& o( j6 ?4 R
|